Zelluna awarded NOK16m research grant for Phase 1 cancer study

Anixa Biosciences' breast cancer vaccine technology granted first Korean patent

Nuvation Bio's taletrectinib Marketing Authorisation Application for advanced ROS1-positive non-small cell lung cancer treatment validated in UK

Natera and Aveta Biomics partner on Phase 3 head and neck cancer trial

AstraZeneca's Datroway recommended for EU approval as first-line treatment in metastatic triple-negative breast cancer

Anivive Lifesciences' Laverdia receives FDA approval to treat canine lymphoma

Racura Oncology doses first patient in Phase 1 lung cancer trial

LyGenesis granted funding for research project to induce immune tolerance to pancreatic islet transplantation

FDA approves Merck's Keytruda combinations for first-line treatment of PD-L1-positive advanced triple-negative breast cancer

Biosidus partners with Mubadala Bio in the UAE

Natera Signatera gains PMDA approval in Japan for colorectal cancer testing

Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy

Oxford BioTherapeutics reports progress in Boehringer Ingelheim partnered programmes

Genprex receives Canadian Patent Allowance for Reqorsa gene therapy combination in lung cancer

Transgene expands myvac platform into non-small cell lung cancer with TG4070